Intetumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Intetumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target integrin alpha-V
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6468H10008N1744O2006S40
Molar mass 145.6 kg/mol
 NYesY (what is this?)  (verify)

Intetumumab is a human monoclonal antibody that was being studied for the treatment of solid tumors.[1]

Intetumumab was developed by Centocor, Inc.

Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.[2]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab" (PDF). American Medical Association. 
  2. ^ "Intetumumab". AdisInsight. Retrieved 30 January 2017.